Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


29th International Conference on Public Mental Health and Neuroscience

Amsterdam, Netherlands

Victor Manolov

Medical University in Sofia, Bulgaria

Title: Atherosclerosis and changed iron metabolism in chronic kidney disease


Biography: Victor Manolov


Chronic kidney disease (CKD) involves high number of population worldwide, which on its way increases brain-vascular diseases risk. Among the main reasons for increased brain disorders evidence in patients with CKD is iron homeostasis disregulation. Impairment of brain cognitive function is an early sign of atherosclerosis development. 65 patients with chronic kidney disease (stages II to V, incl on dialysis) were included; age 48.8 ± 6.9. Their results were compared to sex and age matched healthy control and with CKD patients with no atherosclerotic changes. Routine blood analyses as CBC, serum iron, ferritin, hsCRP and specific hepcidin were measured in the included groups. IMT, MMSE, CERAD tests were used for atherosclerotic changes evaluation. We found increased serum hepcidin levels in CKD patients with IMT, MMSE, CERAD changes (201.8 ± 14.7 μg/L) compared to healthy controls  (20.7 ± 1.9 μg/L) and CKD with no atherosclerotic changes group (174.4 ± 11.8 μg/L); P<0.005. A positive correlation was found in CKD patients with brain disorders between IMT and serum hepcidin levels (r=0.838, P<0.01). Serum hepcidin correlates positively to atherosclerotic evidence changes in patients with impaired kidney function (r=0.810, P<0.01). Brain-vascular disease risk factors are connected to chronic kidney function impairment. Disregulation of iron homeostasis is one of the main risk atherogenesis factors. Early hepcidin quantification might predict cognitive disturbances as atherosclerosis symptoms in chronic kidney disease patients, which might be very important for better clinical diagnosis and practice.

Acknowledgements: This project is sponsored by MU-Sofia, as part of Grant Д-235/2017.